Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages ov...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kleintjens, Joris, Li, Xiao, Simoens, Steven, Thijs, Vincent, Goethals, Marnix, Rietzschel, Ernst R., Asukai, Yumi, Saka, Ömer, Evers, Thomas, Faes, Petra, Vansieleghem, Stefaan, De Ruyck, Mimi
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2013
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824571/
https://ncbi.nlm.nih.gov/pubmed/24030788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-013-0087-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares